 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CVI-HBV-001 / CHA Vaccine Institute
New P1/2 trial: A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine (clinicaltrials.gov) - Feb 25, 2016
P1/2, N=75, Completed, Sponsor: CHA Vaccine Institute Co., Ltd.